The makers of both liraglutide and semaglutide, Novo Nordisk, are currently conducting two large-scale, placebo-controlled trials to see whether semaglutide can improve the trajectory of people diagnosed with early Alzheimers disease
The company is now testing the molecule in Phase 3 studies
Follow us on all our social media handles to stay connected and engaged with the Society of Pharmaceutical Sciences and Research (SPSR) community, International Journal of Pharmaceutical Sciences and Research (IJPSR), International Journal of Pharmacognosy (IJP) & SPSR Periodicals Pvt Ltd To view or add a comment, sign in 53,660 followers
Drinking plenty of water can support digestion and reduce common side effects like nausea
En GYMER no hemos lanzado una protena ms, hemos diseado, elaborado y fabricado LA PROTENA